(Total Views: 590)
Posted On: 10/15/2021 11:30:41 PM
Post# of 148899
Very good read, thanks.
Leronlimab fixes those.
Regular APOE regulates low-density lipoproteins and helps clear beta amyloid plaques in the brain. The APOE-E4 genetic variation is not as effective and allows an increase in low-density lipoproteins and plaques to accumulate. Inflammation decreases APOE production and TGF-b increases it. Leronlimab downregulates the inflammation and upregulates TGF-b which would increase the effectiveness of both APOE and the crippled APOE-E4.
Quote:
Several candidate mechanisms for CRCI have been hypothesized based on clinical and preclinical studies. Increased systemic inflammation occurs in response to cancer, as well as to chemotherapy, radiotherapy, and surgery. Chronically elevated inflammation can lead to neuroinflammation that could result in neurotoxicity and increased oxidative damage. Evidence has also implicated mitochondrial dysfunction in neurons as well as disrupted neurogenesis and neuroplasticity.
Leronlimab fixes those.
Quote:
Genetic risk for CRCI is an ongoing area of study, with some evidence suggesting particular vulnerability among APOE*E4 carriers, the best-known genetic risk for Alzheimer disease.
Regular APOE regulates low-density lipoproteins and helps clear beta amyloid plaques in the brain. The APOE-E4 genetic variation is not as effective and allows an increase in low-density lipoproteins and plaques to accumulate. Inflammation decreases APOE production and TGF-b increases it. Leronlimab downregulates the inflammation and upregulates TGF-b which would increase the effectiveness of both APOE and the crippled APOE-E4.
Quote:
Cancer-Related Cognitive Impairment in Patients With a History of Breast Cancer
https://jamanetwork.com/journals/jama/fullarticle/2785382
(9)
(0)Scroll down for more posts ▼
